SCHEMBL3335372

SCHEMBL3335372

CCCOc1nc(N)nc2ccc(-c3ccc(F)cc3)cc12

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.45
MAP4K4 O95819 1/20 0.45
SCN9A Q15858 1/20 0.42
CDK1 P06493 1/20 0.39
CCNB1 P14635 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CCNA1 P78396 1/20 0.39
PIK3CA P42336 5/20 0.39
MTOR P42345 5/20 0.39
KCNH2 Q12809 2/20 0.39
PIK3CD O00329 2/20 0.38
GAA P10253 1/20 0.38
DHFR P00374 3/20 0.37
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
NAMPT P43490 1/20 0.36
ADORA1 P30542 1/20 0.36
DHODH Q02127 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3336378 0.94 SCN9A (0.47) ADORA2AMAP4K4SCN9ACDK1CCNB1
SCHEMBL3337583 0.90 MAP4K4 (0.47) ADORA2AMAP4K4SCN9APIK3CAMTOR
SCHEMBL3336135 0.89 SQOR (0.46) ADORA2AMAP4K4SCN9APIK3CAMTOR
SCHEMBL3334911 0.82 DHFR (0.46) PIK3CAMTORPIK3CDDHFRNOS3
SCHEMBL3335665 0.82 PIK3CA (0.47) ADORA2AMAP4K4SCN9APIK3CAMTOR
SCHEMBL3337681 0.82 ADORA2A (0.45) ADORA2AMAP4K4SCN9ACDK2PIK3CA
SCHEMBL3334604 0.81 ADORA2A (0.50) ADORA2AMAP4K4SCN9ACDK1CCNB1
SCHEMBL3340775 0.80 MAPK10 (0.44) MAP4K4
SCHEMBL3334263 0.80 MAP4K4 (0.55) MAP4K4
SCHEMBL3337266 0.80 SLC2A1 (0.42) ADORA2AMAP4K4SCN9ACDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 ADORA2A 1968/4885MAP4K4 2433/4885SCN9A 225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.